This IOIBD consensus supports the integration of AI/ML into central reading for IBD clinical trials to improve objectivity, efficiency, and consistency, while maintaining human oversight. Further research should address validation, regulatory frameworks, and multimodal integration to enable broader adoption in both trials and clinical practice.
IOlBD evidence-based consensus on the use of artificial intelligence for assessment of endoscopic and histologic endpoints in clinical trials of inflammatory bowel disease
Axel Dignass·Walter Reinisch·F Magro·Bruce E Sands·Silvio Danese·Dan Turner·Gerassimos J. Mantzaris·Marietta Iacucci·Laurent Peyrin-Biroulet·Vipul Jairath·Neeraj Narula·David T Rubin·Iris Dotan·Edward V Loftus·Krishan Pratap
